The global high potency active pharmaceutical ingredients (HPAPI) market is expected to reach USD 24.09 Billion by 2021 from USD 16.02 Billion in 2016, growing at a CAGR of 8.5% from 2016 to 2021.
On the basis of type, the high potency active pharmaceutical ingredients market is segmented into innovative and generic HPAPIs. The innovative HPAPIs segment is estimated to account for the larger share of the total HPAPIs market. The large share of this segment is attributed to the presence of large number of patent-protected innovative HPAPIs, their higher price as compared to generics, growing focus of major players on the development of novel high-potency products, and the growing demand for novel high-potency cancer therapeutics. On the basis of type of manufacturer, the high potency active pharmaceutical ingredients market is segmented into captive and merchant HPAPI manufacturers.
The HPAPIs market, on the basis of type of synthesis, is segmented into synthetic and biotech HPAPIs. Synthetic HPAPIs is estimated to dominate this market in 2016.The large share of this segment can be attributed to the increasing emergence of new molecules in the market, rising number of new product approvals, technological advancements in synthesis, and ease of production. However, the biotech APIs market is expected to grow at a substantially higher rate during the forecast period owing to Advances in biotechnology, growing demand for antibody drug conjugates, growing demand due to their specificity in action, their similarity with the natural biological compounds, and significant growth in the demand for monoclonal antibodies.
Based on therapeutic application, the high potency active pharmaceutical ingredients market is segmented into oncology, hormonal imbalance, glaucoma, and other therapeutic applications. The oncology segment is estimated to account for the largest share of the global HPAPIs market in 2016. The growing incidence and prevalence of cancer across the globe and the launch of new target therapies in addition to technological advancements in the oncology HPAPI-antibody conjugate technology are major factors contributing to the growth of this application segment.
Based on geography, the global high potency active pharmaceutical ingredients market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market by the end of 2016. This large share can be attributed to various factors growing incidence of cancer, increasing investments in cancer research especially targeted therapies, increasing demand for cancer HPAPIs, technological advancements in HPAPI manufacturing, growing CMOs market.
Prominent players in the high potency active pharmaceutical ingredients market include Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), and Mylan Inc. (U.S.).
About MarketsandMarkets : MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
